{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:54:57Z","timestamp":1793656497119,"version":"4.5.1"},"reference-count":39,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"unspecified","delay-in-days":30,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["72342014"],"award-info":[{"award-number":["72342014"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sichuan Science and Technology Programme","award":["2022YFH0114"],"award-info":[{"award-number":["2022YFH0114"]}]},{"name":"1.3.5 Projects for Disciplines of Excellence Clinical Research Incubation West China Hospital, Sichuan University","award":["2020HXF011"],"award-info":[{"award-number":["2020HXF011"]}]},{"name":"1.3.5 Projects for Disciplines of Excellence Clinical Research Incubation West China Hospital, Sichuan University","award":["ZYJC18010"],"award-info":[{"award-number":["ZYJC18010"]}]},{"name":"1.3.5 Projects for Disciplines of Excellence Clinical Research Incubation West China Hospital, Sichuan University","award":["ZYYC24001"],"award-info":[{"award-number":["ZYYC24001"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["bmjmed"],"accepted":{"date-parts":[[2024,9,13]]},"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To examine cardiovascular and kidney benefits and harms of sodium-glucose co-transporter-2 (SGLT-2) inhibitors stratified by risk in adults with chronic kidney disease regardless of diabetes status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Systematic review and meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources<\/jats:title>\n                    <jats:p>Ovid Medline, Embase, and Cochrane Central from database inception to 15 June 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Eligibility criteria for selecting studies<\/jats:title>\n                    <jats:p>Randomised controlled trials that compared SGLT-2 inhibitors with placebo or standard care with no SGLT-2 inhibitors in adults with chronic kidney disease with a follow-up duration of \u226512 weeks were eligible. Secondary analyses based on subpopulations from randomised controlled trials and publications not in English language were excluded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data synthesis<\/jats:title>\n                    <jats:p>Random effects meta-analyses were conducted, with effect estimates presented as risk ratios with 95% confidence intervals (CIs). Absolute treatment effects were estimated over a five\u2009year duration for individuals with varied risks of cardiovascular and kidney complications based on the Kidney Disease Improving Global Outcomes (KDIGO) risk stratification system. Certainty of evidence was assessed using the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Evidence from 13 randomised controlled trials (29\u2009614 patients) informed treatment effect estimates. In relative terms, SGLT-2 inhibitors reduced all cause death (risk ratio 0.85 (95%\u2009CI 0.74 to 0.98)), cardiovascular death (0.84 (0.74 to 0.96)), kidney failure (0.68 (0.60 to 0.77)), non-fatal stroke (0.73 (0.57 to 0.94)), non-fatal myocardial infarction (0.75 (0.60 to 0.93)), and admission to hospital for heart failure (0.68 (0.60 to 0.78)). No credible subgroup effects were found from diabetes status, heart failure status, estimated glomerular filtration rate, urinary albumin-to-creatinine ratio, and follow-up duration. Absolute effect estimates across these outcomes over a five\u2009year period varied across risk groups based on baseline risks of cardiovascular and kidney events. Effects of SGLT-2 inhibitors in the group at low risk included seven fewer all- cause deaths, four fewer admissions to hospital for heart failure per 1000 individuals, and no effects on kidney failure. Effects in the higher risk group included 48 fewer all cause deaths, 58 fewer kidney failures, and 25 fewer admissions to hospital for heart failure per 1000 individuals. Although SGLT-2 inhibitor use was associated with a relative increase in the risk of harms, including genital infection (2.66 (95%\u2009CI 2.07 to 3.42)), ketoacidosis (2.27 (1.30 to 3.95)), and symptomatic hypovolaemia (1.29 (1.15 to 1.44)), absolute differences for all harm outcomes were small.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Among people who have chronic kidney disease either with type 2 diabetes or not, SGLT-2 inhibitors improved cardiovascular and kidney outcomes with varying degrees of absolute benefit depending on an individual's baseline risks of cardiovascular and kidney-related sequelae. Absolute benefits and harms stratified by risk and associated with SGLT-2 inhibitors should inform individual decision making at the patient level.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>PROSPERO CRD42022325483.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjmed-2024-001009","type":"journal-article","created":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T08:10:14Z","timestamp":1727770214000},"page":"e001009","source":"Crossref","is-referenced-by-count":14,"title":["Sodium-glucose co-transporter-2 inhibitors in patients with chronic kidney disease with or without type 2 diabetes: systematic review and meta-analysis"],"prefix":"10.1136","volume":"3","author":[{"given":"Xinyu","family":"Zou","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Metabolism, MAGIC China Centre, West China Hospital of Sichuan University, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyang","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, MAGIC China Centre, West China Hospital of Sichuan University, Chengdu, Sichuan, China"},{"name":"Faculty of Science and Engineering, University of Groningen, Groningen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Olav Vandvik","sequence":"additional","affiliation":[{"name":"Department of Medicine, Lovisenberg Diaconal Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunhe","family":"Mao","sequence":"additional","affiliation":[{"name":"Sports Medicine Centre, West China Hospital of Sichuan University, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0931-7851","authenticated-orcid":false,"given":"Arnav","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada"},{"name":"Department of Medicine, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belen","family":"Ponte","sequence":"additional","affiliation":[{"name":"Service of Nephrology and Hypertension, Geneva University Hospitals, Geneve, Gen\u00e8ve, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxi","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Nephrology, West China Hospital of Sichuan University, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2352-5718","authenticated-orcid":false,"given":"Gordon","family":"Guyatt","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinbo","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, West China Hospital of Sichuan University, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianghang","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Endocrinology Research Centre, Xiangya Hospital Central South University, Changsha, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2627-1250","authenticated-orcid":false,"given":"Chang","family":"Xu","sequence":"additional","affiliation":[{"name":"Proof of Concept Centre, Eastern Hepatobiliary Surgery Hospital, Third Affiliated Hospital, Second Military Medical University, Naval Medical University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, West China Hospital of Sichuan University, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoming","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, MAGIC China Centre, West China Hospital of Sichuan University, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Agoritsas","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada"},{"name":"Division of General Internal Medicine, Department of Medicine, University Hospitals of Geneva, Geneva, Gen\u00e8ve, Switzerland"},{"name":"MAGIC Evidence Ecosystem Foundation, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0060-0287","authenticated-orcid":false,"given":"Sheyu","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, MAGIC China Centre, West China Hospital of Sichuan University, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,10,1]]},"reference":[{"key":"2025080501055852000_3.1.e001009.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30045-3"},{"key":"2025080501055852000_3.1.e001009.2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2015.10.011"},{"key":"2025080501055852000_3.1.e001009.3","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-074068","article-title":"Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials","volume":"381","author":"Shi","year":"2023","journal-title":"BMJ"},{"key":"2025080501055852000_3.1.e001009.4","doi-asserted-by":"crossref","first-page":"851","DOI":"10.7326\/M21-4284","article-title":"Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Heart Failure: A Systematic Review and Meta-analysis","volume":"175","author":"Zou","year":"2022","journal-title":"Ann Intern Med"},{"key":"2025080501055852000_3.1.e001009.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811744"},{"key":"2025080501055852000_3.1.e001009.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024816"},{"key":"2025080501055852000_3.1.e001009.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204233"},{"key":"2025080501055852000_3.1.e001009.8","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","year":"2022","journal-title":"Lancet"},{"key":"2025080501055852000_3.1.e001009.9","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.i5191","article-title":"Introduction to BMJ Rapid Recommendations","volume":"354","author":"Siemieniuk","year":"2016","journal-title":"BMJ"},{"key":"2025080501055852000_3.1.e001009.10","first-page":"1","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"2025080501055852000_3.1.e001009.11","doi-asserted-by":"crossref","unstructured":"Agarwal A , Zeng X , Li S , et al . Sodium-glucose co-transporter-2 (SGLT-2) inhibitors for adults with chronic kidney disease: a clinical practice guideline. BMJ 2024.","DOI":"10.1136\/bmj-2024-080257"},{"key":"2025080501055852000_3.1.e001009.12","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2025080501055852000_3.1.e001009.13","doi-asserted-by":"publisher","DOI":"10.2307\/2531052"},{"key":"2025080501055852000_3.1.e001009.14","doi-asserted-by":"publisher","DOI":"10.3102\/10769986030003261"},{"key":"2025080501055852000_3.1.e001009.15","doi-asserted-by":"publisher","DOI":"10.1111\/j.0006-341X.2000.00455.x"},{"key":"2025080501055852000_3.1.e001009.16","doi-asserted-by":"publisher","DOI":"10.2307\/2533446"},{"key":"2025080501055852000_3.1.e001009.17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629"},{"key":"2025080501055852000_3.1.e001009.18","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.200077"},{"key":"2025080501055852000_3.1.e001009.19","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/jrsm.1370","article-title":"Random-effects meta-analysis of few studies involving rare events","volume":"11","author":"G\u00fcnhan","year":"2020","journal-title":"Res Synth Methods"},{"key":"2025080501055852000_3.1.e001009.20","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jclinepi.2019.03.012","article-title":"The statistical significance of meta-analyses is frequently fragile: definition of a fragility index for meta-analyses","volume":"111","author":"Atal","year":"2019","journal-title":"J Clin Epidemiol"},{"key":"2025080501055852000_3.1.e001009.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2022.05.033"},{"key":"2025080501055852000_3.1.e001009.22","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4040"},{"key":"2025080501055852000_3.1.e001009.23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39489.470347.AD"},{"key":"2025080501055852000_3.1.e001009.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2021.03.026"},{"key":"2025080501055852000_3.1.e001009.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2012.01.012"},{"key":"2025080501055852000_3.1.e001009.26","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2013.356"},{"key":"2025080501055852000_3.1.e001009.27","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13413"},{"key":"2025080501055852000_3.1.e001009.28","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S2213-8587(19)30086-5","article-title":"Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial","volume":"7","author":"Pollock","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025080501055852000_3.1.e001009.29","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12348"},{"key":"2025080501055852000_3.1.e001009.30","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S2213-8587(13)70208-0","article-title":"Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial","volume":"2","author":"Barnett","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025080501055852000_3.1.e001009.31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA2030186"},{"key":"2025080501055852000_3.1.e001009.32","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1111\/dom.15019","article-title":"Efficacy and safety of sotagliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease","volume":"25","author":"Cherney","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"2025080501055852000_3.1.e001009.33","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1111\/dom.14513","article-title":"Efficacy and safety of sotagliflozin in patients with type 2 diabetes and severe renal impairment","volume":"23","author":"Cherney","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"2025080501055852000_3.1.e001009.34","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-017-0337-5"},{"key":"2025080501055852000_3.1.e001009.35","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2019.03.417"},{"key":"2025080501055852000_3.1.e001009.36","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.310"},{"key":"2025080501055852000_3.1.e001009.37","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2019030238"},{"key":"2025080501055852000_3.1.e001009.38","unstructured":"Gansevoort R . A randomized controlled clinical trial to assess the effect of dapagliflozin on renal and cardiovascular outcomes in patients with severe chronic kidney disease. clinicaltrials.gov; 2023. Available: https:\/\/clinicaltrials.gov\/study\/NCT05374291 [Accessed 1 Jan 2024]."},{"key":"2025080501055852000_3.1.e001009.39","unstructured":"University of Colorado, Denver . Feasibility of study of empagliflozin in patients with autosomal dominant polycystic kidney disease. clinicaltrials.gov; 2023. Available: https:\/\/clinicaltrials.gov\/study\/NCT05510115 [Accessed 1 Jan 2024]."}],"container-title":["BMJ Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjmed-2024-001009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T08:06:06Z","timestamp":1754381166000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjmedicine.bmj.com\/lookup\/doi\/10.1136\/bmjmed-2024-001009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,10,1]]},"published-print":{"date-parts":[[2024,9]]}},"alternative-id":["10.1136\/bmjmed-2024-001009"],"URL":"https:\/\/doi.org\/10.1136\/bmjmed-2024-001009","relation":{},"ISSN":["2754-0413"],"issn-type":[{"value":"2754-0413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9]]}}}